Norethisterone and gestational diabetes

In a single practice during the 21 years 1971-1991, the incidence of gestational diabetes in pregnancies in which norethisterone was prescribed was 32.4% (22 of 69) in comparison with 7.1% in pregnancies in which the women did not take norethisterone (137 of 1,684) (p < 0.001). Gestational diabet...

Full description

Saved in:
Bibliographic Details
Published inAustralian & New Zealand journal of obstetrics & gynaecology Vol. 32; no. 3; p. 233
Main Authors Beischer, N A, Cookson, T, Sheedy, M, Wein, P
Format Journal Article
LanguageEnglish
Published Australia 01.08.1992
Subjects
Adult
Clitoris - pathology
Diabetes, Gestational - chemically induced
Diabetes, Gestational - drug therapy
Female
Follow-Up Studies
Glucose Tolerance Test
Humans
Hypertrophy - chemically induced
Infant Mortality
Infant, Newborn
Insulin - therapeutic use
Middle Aged
Norethindrone - adverse effects
Pregnancy
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:In a single practice during the 21 years 1971-1991, the incidence of gestational diabetes in pregnancies in which norethisterone was prescribed was 32.4% (22 of 69) in comparison with 7.1% in pregnancies in which the women did not take norethisterone (137 of 1,684) (p < 0.001). Gestational diabetes was no less severe (degree of hyperglycaemia, need for insulin therapy) when associated with norethisterone. However, follow-up revealed that gestational diabetes when associated with norethisterone had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance. Masculinization of a female fetus occurred in 5 of 39 (12.8%) exposed to norethisterone; all were cases of clitoral hypertrophy not requiring surgical treatment. Norethisterone in these 69 pregnancies accounted for 33.3% (5 of 15) cases of clitoral hypertrophy diagnosed in 100,756 consecutive births.
ISSN:0004-8666
DOI:10.1111/j.1479-828X.1992.tb01954.x